Key facts
- This page summarizes Philip A. Serlin's Form 3 filing for BioLineRx Ltd. (BLRX).
- 0 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 27 Mar 2026, 16:05.
Philip A. Serlin - 18 Mar 2026 Form 3 Insider Report for BioLineRx Ltd. (BLRX)
- Reporting relationship
- Chief Executive Officer
- Issuer ticker
- BLRX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Philip Serlin
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Philip A. Serlin filed Form 3 for BioLineRx Ltd. (BLRX) on 27 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001493277
Primary reporting owner
Serlin Philip A
- Relationship
- Chief Executive Officer
- Address
- BIOLINERX LTD., 2 HAMA'AYAN STREET, MODII'N, ISRAEL
- Signature
- /s/ Philip Serlin
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BLRX
holding
Ordinary Shares, 0.1 NIS per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,131,800
- Date
- 18 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BLRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 55,800
- Exercise price
- $0.2640
- Footnotes
- F1, F2, F9
BLRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 316,200
- Exercise price
- $0.2840
- Footnotes
- F1, F3, F9
BLRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 719,400
- Exercise price
- $0.2850
- Footnotes
- F1, F4, F9
BLRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,136,400
- Exercise price
- $0.2870
- Footnotes
- F1, F5, F9
BLRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,301,200
- Exercise price
- $0.1520
- Footnotes
- F1, F6, F9
BLRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 4,194,600
- Exercise price
- $0.1020
- Footnotes
- F1, F7, F9
BLRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 4,495,200
- Exercise price
- $0.0450
- Footnotes
- F1, F8, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Options granted under the 2003 Amended and Restated Share Incentive Plan.
Footnote F2
The grant date of this grant is October 10, 2016. This option grant is fully vested as of this date.
Footnote F3
The grant date of this grant is July 05 ,2017. This option grant is fully vested as of this date.
Footnote F4
The grant date of this grant is April 16, 2018. This option grant is fully vested as of this date.
Footnote F5
The grant date of this grant is November 07, 2019. This option grant is fully vested as of this date.
Footnote F6
The grant date of this grant is April 05, 2021. This option grant is fully vested as of this date.
Footnote F7
The grant date of this grant is August 15, 2022. This option grant is fully vested as of this date.
Footnote F8
The grant date of this grant is September 06, 2023. As of this date, 3,090,600 options of this grant are vested. The remaining 1,404,600 options will vest in equal 5 quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
Footnote F9
To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.